Alexion intends to file for the approval of the SC formulation of the drug and device combination in PNH and atypical hemolytic uremic syndrome (aHUS) indications in the United States and the EU, once this study is completed and 12-month safety data are collected.Meanwhile, taking a lead from other biotechs like Incyte INCY, Amgen AMGN and Gilead Sciences, Inc. GILD, Alexion has also initiated a phase III study on Ultomiris in a subset of adults suffering from COVID-19 and a positive outcome will boost prospects significantly.